<> "The repository administrator has not yet configured an RDF license."^^ . <> . . "Characterization of the transcription factor MEOX2 as a potential oncogene in gliomas"^^ . "Glioblastoma (GBM) is the most aggressive tumor of the central nervous system. Median\r\nsurvival time is 15 months from diagnosis. Standard of care for GBM patients includes surgery,\r\nradiation and chemotherapy. All known therapies for GBM patients do not lead to prolonged\r\nsurvival. Some targeted therapies can lead to a prolonged progression free survival. Overall\r\nsurvival of patients however is not increased by any available therapy option. MEOX2 is a\r\nhomeobox-transcription factor. It is highly upregulated during embryogenesis and responsible\r\nfor the development of muscles, angiogenesis and limb development. MEOX2 can regulate the\r\nepithelial-mesenchymal transition of cells via cyclin dependent kinase signaling. MEOX2 is\r\nnot expressed in the adult brain tissue however is significantly upregulated in GBM and\r\ncorrelates with tumor grade. High MEOX2 expression in gliomas is generally correlated with\r\na worse clinical prognosis for patients, underlining the potential role of MEOX2 in\r\ntumorigenesis. As current therapy options can not provide a cure for GBM, it is crucial to\r\nunderstand the role of MEOX2 and reveal candidates connected to the malignant transformation\r\nof gliomas for further investigations. In a lower grade progression free state, glioma could be\r\ntreated like a chronic disease. Therefore, I identified MEOX2 regulatory effect on cancer\r\nassociated pathways and unraveled the target genes of MEOX2 in two GBM patient-derived\r\ntumorsphere lines. I also identified an ERK phosphorylation site in MEOX2 in the GBM\r\ntumorsphere line (S155) and elucidated the nuclear MEOX2 protein distribution depending on\r\nits phosphorylation status. I was also able to identify MEOX2 as an oncogene in vivo, using a\r\nxenograft mouse model where I observed increased proliferation upon MEOX2 overexpression\r\nin a GBM tumorsphere line that exhibits slower growth kinetics. Lastly, I observed MEOX2\r\nknockdown in one of two GBM tumorsphere lines reduced sensitivity to EGF activated ERK\r\nphosphorylation that was reversed by a MEK inhibitor. All results indicate a role of MEOX2\r\nas an oncogene in gliomas, and MEOX2 may serve as a future prognostic marker in gliomas. It\r\nis favourable to identify GBM in an early state which is currently not possible due to diagnosis\r\nbased on MRI scans, this way GBM has a lower amount of lesions and accumulated mutations,\r\nwhich are gained in tumor development."^^ . "2022" . . . . . . . "Anna"^^ . "Schönrock"^^ . "Anna Schönrock"^^ . . . . . . "Characterization of the transcription factor MEOX2 as a potential oncogene in gliomas (Other)"^^ . . . . . . "lightbox.jpg"^^ . . . "Characterization of the transcription factor MEOX2 as a potential oncogene in gliomas (Other)"^^ . . . . . . "preview.jpg"^^ . . . "Characterization of the transcription factor MEOX2 as a potential oncogene in gliomas (Other)"^^ . . . . . . "medium.jpg"^^ . . . "Characterization of the transcription factor MEOX2 as a potential oncogene in gliomas (Other)"^^ . . . . . . "small.jpg"^^ . . . "Characterization of the transcription factor MEOX2 as a potential oncogene in gliomas (PDF)"^^ . . . "Dissertation Anna Schoenrock 2021.pdf"^^ . . . "Characterization of the transcription factor MEOX2 as a potential oncogene in gliomas (Other)"^^ . . . . . . "indexcodes.txt"^^ . . "HTML Summary of #30929 \n\nCharacterization of the transcription factor MEOX2 as a potential oncogene in gliomas\n\n" . "text/html" . . . "500 Naturwissenschaften und Mathematik"@de . "500 Natural sciences and mathematics"@en . .